Strong chemotherapy may
increase your risk of infection.1
Neulasta® can help.2
Neulasta® helps reduce the risk of infection by boosting your white blood cell count to strengthen your immune system.2
Neulasta® (pegfilgrastim) is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.2
It is not known if Neulasta® is safe and effective in children.2
Neulasta® has possible serious side effects. Do not take Neulasta® if you have had a serious allergic reaction to Neulasta® (pegfilgrastim) or to NEUPOGEN® (filgrastim).2 Please see additional Important Safety Information.Learn About Neulasta®
Now there’s another way to get your Neulasta®3
The On-body Injector for Neulasta® is designed to deliver your Neulasta® dose approximately 27 hours after receiving chemotherapy.
Neulasta® reduced infection risk
by 94% in patients given
In a key study, 17% of patients not treated with Neulasta® got an infection vs 1% of patients treated with Neulasta®.See Study Results
Neulasta® is the #1 prescribed
white blood cell booster to help reduce the risk of infection during strong chemotherapy5
Learn about cancer patients who used Neulasta® to help reduce their risk of infection during strong chemotherapy.See Real Patient Stories
Financial assistance for eligible patients
The Neulasta FIRST STEP® Program may help eligible patients with the out-of-pocket cost of Neulasta® treatment.Get Details
- Wujcik D. Infection. In: Groenwald SL, Goodman M, Frogge MH, Yarbro CH, eds. Cancer Symptom Management. Boston, Mass: Jones & Bartlett Publishers; 1996:289-304.
- Neulasta® (pegfilgrastim) Patient Product Information, Amgen.
- Neulasta® (pegfilgrastim) Patient Instructions For Use, Amgen.
- Vogel CL, Wotjukiewicz MZ, Carroll RR, et al. J Clin Oncol. 2005;23:1178-1184.
- Amgen. Data on file.